Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Zimbabwe Pharmaceuticals And Healthcare
Industry SWOT — 6
Zimbabwe Political
SWOT — 7
Zimbabwe Economic SWOT — 8
Zimbabwe Business Environment SWOT — 9
Pharmaceutical
Business Environment Ratings — 10
Table: Middle East and
Africa (MEA) - Regional Pharma Business Environment Ratings For
Q309 — 10
Limits of Potential
Returns — 11
Risks to Realisation of
Returns — 12
Zimbabwe – Market
Summary — 13
Regulatory Regime — 14
Intellectual Property Developments — 14
Pricing and
Reimbursement Issues — 15
Public Drug
Procurement — 15
Industry
Developments — 17
Epidemiology — 17
Communicable Diseases — 18
Cholera
Crisis — 18
HIV/AIDS Situation — 20
Healthcare System — 21
Healthcare
Funding — 23
Recent Healthcare System
Developments — 24
Healthcare
Staff — 25
Pharmaceutical Sector — 27
Recent Pharmaceutical Sector Developments — 29
Table: ARV
Prices Available Through Direct Purchase From Roche
(CHF) — 31
Pharmacy Sector — 31
Traditional Medicine — 32
Biotechnology Sector
Developments — 32
Medical Devices — 33
Industry Forecast Scenario — 34
Overall Market
Forecasts — 34
Table: Zimbabwe - Drug Market Forecast,
Historical Data and Forecasts — 35
Key Growth Factors
– Industry — 36
Key Growth Factors –
Macroeconomic — 38
Table: Zimbabwe - Economic
Activity — 39
Prescription Drug Market
Forecast — 40
Table: Zimbabwe - Prescription Drug Market
Indicators, Historical Data and Forecasts (US$mn unless otherwise
indicated) — 40
Patented Drug Market
Forecast — 42
Table: Zimbabwe - Patented Market Forecast,
Historical Data and Forecasts — 42
Generic Drug Market
Forecast — 43
Table: Zimbabwe - Generic Drug Market
Indicators*, Historical Data and Forecasts — 43
OTC Drug
Market Forecast — 44
Table: Zimbabwe - OTC Drug Market
Forecast, Historical Data and Forecasts (US$mn unless otherwise
indicated) — 45
Pharmaceutical Trade
Forecasts — 46
Table: Zimbabwe - Pharmaceutical Trade
Balance, Historical Data and Forecasts (US$mn) — 46
Other
Healthcare Data Forecasts — 47
Table: Zimbabwe - Other
Healthcare Forecasts, Historical Data and Forecasts — 47
Key Risks to BMI Forecasts — 48
Competitive
Landscape — 49
Company Profiles — 50
Multinational Companies — 50
Ranbaxy — 50
Pfizer — 52
Novartis — 54
Sanofi-Aventis — 55
Merck & Co — 56
GlaxoSmithKline — 57
Indigenous Companies — 59
Datlabs — 59
Varichem Laboratories — 61
CAPS
Holdings — 63
Country Snapshot: Zimbabwe Demographic
Data — 66
Section 1: Population — 66
Table: Demographic Indicators, 2005-2030 — 66
Table:
Rural/Urban Breakdown, 2005-2030 — 67
Section 2: Education
and Healthcare — 67
Table: Education,
2000-2003 — 67
Table: Vital Statistics,
2005-2030 — 67
Section 3: Labour Market and Spending
Power — 68
Table: Employment Indicators, 1997 And
1999* — 68
Table: Average Annual Manufacturing Wages,
1996-2002 — 68
BMI Forecast
Modelling — 69
How We Generate Our Pharmaceutical Industry
Forecasts — 69
Pharmaceutical Business Environment Ratings
Methodology — 70
Ratings Overview — 70
Table: Pharmaceutical Business Environment Indicators — 71
Weighting — 72
Table: Weighting Of
Components — 72
Sources — 72
| 
View Cart
